Cowen analyst Joseph Thome reiterated an Outperform rating on Evelo Biosciences Inc (NASDAQ: EVLO), following the company's announcement it's shifting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE